Navigation Links
FDA Clears GeNO LLC's Investigational New Drug Application for Clinical Trials With Its NITROSYL™ Inhaled Nitric Oxide System
Date:12/2/2010

COCOA, Fla., Dec. 2, 2010 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a clinical trial with the GeNO NITROSYL™ (Inhaled Nitric Oxide) System for treatment of pulmonary hypertension in patients with Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) and Pulmonary Arterial Hypertension, (PAH, WHO Group 1).

This FDA clearance enables GeNO to begin a US, multicenter, Phase 2 dose escalation study in which both patient populations will receive up to a maximum of 80 parts per million (ppm) of Nitric oxide (NO) delivered for up to 150 minutes with GeNO's stand-alone NITROSYL™ platform. The study is subject to Institutional Review Board (IRB) approval.

"The clearance of this IND is a major milestone for the company as we are committed to developing treatment for these grave chronic conditions," commented GeNO LLC Founder and President David Fine, Ph.D.  "Today's development also lays the groundwork for our patented ambulatory platform, which has the potential to greatly expand the use of inhaled nitric oxide to many new chronic indications due to its simplicity and ease-of-use."

GeNO's stand-alone gas cylinder stores premixed nitric oxide as nitrogen dioxide in either air or oxygen.  The gas is allowed to flow through a proprietary cartridge containing ascorbic acid, which generates nitric oxide immediately prior to inhalation.  A second cartridge is provided for redundancy.  The company has also developed the GeNO Ambulatory NITROSYL™ System, which is a hand-held unit with a disposable liquid source. This portable unit snaps into a small, battery-operated pump module attached to a hip or arm holster and provides up to a four-day continuous supply of inhaled nitric oxide for chronic use.  

"This IND moves GeNO's product from a diagnostic to a treatment setting, and the planned dose-escalation study with the gas cylinder will inform the final design of GeNO's NITROSYL™ ambulatory platform," said GeNO Vice President Robert F. Roscigno, Ph.D.  "This regulatory clearance by the FDA is an important step in our efforts to develop the NITROSYL™ platform and expand our focus on developing and commercializing novel therapeutics for chronic, life-threatening diseases."

No medications are currently approved for treatment of pulmonary hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF).  IPF is characterized by progressive fibrosis in the lungs with a median survival time from diagnosis of two to five years and a five-year survival rate of approximately 20 percent.  

Pulmonary arterial hypertension (PAH) is a rare progressive disorder that carries a poor prognosis and is associated with significant morbidity and mortality, having an historical survival rate rarely exceeding five years.  

In March 2010, the FDA approved the company's IND to test the NITROSYL™ stand-alone gas cylinder as a diagnostic agent in PAH. The resulting Phase 2 trial is ongoing for the diagnostic indication.  

ABOUT GENO LLCGeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized.  The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including acute in-hospital care, ambulatory and in-home use for potential chronic treatment.  GeNO's platforms have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for PAH.  The company has five issued US patents with additional patent applications pending. Media Contacts: Carla Burigatto, 610-457-2178

Brian Heffron, 781-799-9568cburigatto@gmail.com

bheffron@ctpboston.com
'/>"/>

SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Volpara™ Breast Imaging Software for Automatic Calculation of Volumetric Breast Density
2. FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain
3. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
4. FDA Clears AirStrip RPM for CRITICAL CARE & CARDIOLOGY Remote Patient Monitoring Solutions
5. FDA Clears Xlumenas NAVIX(TM) Access Device
6. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
7. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
8. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
9. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
10. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
11. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 On ... Committee honored excellence in research, development and innovation in ... gala dinner was held in the presence of Sergey ... Russian Federation , Natalia Sanina, First ... Mikhail Murashko , Head of Roszdravnadzor, National Service of ...
(Date:12/2/2016)... CVS Health Corporation (NYSE: CVS ... City on Thursday, December 15, 2016, beginning at 8:00 a.m. (ET). Senior ... an in-depth review of the company,s strategies to drive ... also discuss 2017 earnings guidance during the event. ... will be broadcast simultaneously on the Investor Relations portion ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite and the ... Dow Jones Industrial Average managed to stay in green. Losses ... prompted Stock-callers this morning to look at the performances of ... ), Smith & Nephew PLC (NYSE: SNN ), ... Therapeutics Inc. (NASDAQ: KOOL ). You can access ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global law ... 21st Drug & Medical Device Litigation Conference , taking place in New York Dec. ... chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the Trial ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a ... SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories ... and disposal. The new version is a faster and a more efficient product, ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):